Employees: 03 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2006-08-01 (19 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LE MESNIL-ESNARD (76240), Seine-Maritime
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE MABILAIS DELAPLASSETTE : revenue, balance sheet and financial ratios
PHARMACIE MABILAIS DELAPLASSETTE is a French company
founded 19 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LE MESNIL-ESNARD (76240),
this company of category PME
shows in 2024 a net income positive of 88 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE MABILAIS DELAPLASSETTE (SIREN 490123114)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
87 672 €
44 279 €
273 126 €
105 984 €
72 202 €
65 389 €
73 742 €
43 515 €
47 479 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIE MABILAIS DELAPLASSETTE generates positive net income of 88 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 47 k€ -> 88 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
87 672 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 18%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 69%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
18.275%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
69.126%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
141.228
128.212
104.812
87.638
67.002
52.401
33.258
27.574
18.275
Financial autonomy
35.309
37.615
43.836
47.534
51.865
55.147
62.208
65.887
69.126
Repayment capacity
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
18.272024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good
In 2024, the debt ratio of PHARMACIE MABILAIS DELAPL... (18.27) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
69.13%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good+5 pts over 3 years
In 2024, the financial autonomy of PHARMACIE MABILAIS DELAPL... (69.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 114.75. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
99.956
146.066
158.996
155.336
138.917
131.033
155.824
130.2
114.745
Interest coverage
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
114.752024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Watch-7 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE MABILAIS DELAPL... (114.75) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Positioning of PHARMACIE MABILAIS DELAPLASSETTE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE MABILAIS DELAPLASSETTE is estimated at
1 223 965 €
(range 852 350€ - 1 831 123€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
852k€1223k€1831k€
1 223 965 €Range: 852 350€ - 1 831 123€
NAF 5 année 2024
Valuation method used
Net Income Multiple
87 672 €
×
14.0x
=1 223 966 €
Range: 852 351€ - 1 831 123€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE MABILAIS DELAPLASSETTE with other companies in the same sector:
Frequently asked questions about PHARMACIE MABILAIS DELAPLASSETTE
What is the revenue of PHARMACIE MABILAIS DELAPLASSETTE ?
The revenue of PHARMACIE MABILAIS DELAPLASSETTE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE MABILAIS DELAPLASSETTE profitable?
Yes, PHARMACIE MABILAIS DELAPLASSETTE generated a net profit of 88 k€ in 2024.
Where is the headquarters of PHARMACIE MABILAIS DELAPLASSETTE ?
The headquarters of PHARMACIE MABILAIS DELAPLASSETTE is located in LE MESNIL-ESNARD (76240), in the department Seine-Maritime.
Where to find the tax return of PHARMACIE MABILAIS DELAPLASSETTE ?
The tax return of PHARMACIE MABILAIS DELAPLASSETTE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE MABILAIS DELAPLASSETTE operate?
PHARMACIE MABILAIS DELAPLASSETTE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart